{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:30:06Z","timestamp":1790231406609,"version":"4.1.0"},"reference-count":24,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019832","name":"Gal\u00e1pagos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,10,13]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>GLPG1205 is a selective functional antagonist of G-protein-coupled receptor 84, which plays an important role in fibrotic processes. This study assessed the efficacy, safety and tolerability of GLPG1205 for treatment of idiopathic pulmonary fibrosis (IPF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PINTA (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link>\n                      :\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03725852\">NCT03725852<\/jats:ext-link>\n                      ) was a phase 2, randomised, double-blind, placebo-controlled, proof-of-concept trial. Patients with IPF were randomised 2:1 to once-daily oral GLPG1205 100\u2005mg or placebo for 26\u2005weeks and stratified to receive GLPG1205 alone or with local standard of care (nintedanib or pirfenidone). The primary end-point was change from baseline in forced vital capacity (FVC); other end-points were safety and tolerability, and lung volumes measured by imaging (high-resolution computed tomography). The study was not powered for statistical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 68 patients received study medication. Least squares mean change from baseline in FVC at week 26 was \u221233.68 (95% CI \u2212112.0\u201344.68)\u2005mL with GLPG1205 and \u221276.00 (95% CI \u2212170.7\u201318.71)\u2005mL with placebo (least squares mean difference 42.33 (95% CI \u221281.84\u2013166.5)\u2005mL; p=0.50). Lung volumes by imaging declined \u221258.30\n                      <jats:italic>versus<\/jats:italic>\n                      \u2212262.72\u2005mL (whole lung) and \u221233.68\n                      <jats:italic>versus<\/jats:italic>\n                      \u2212135.48\u2005mL (lower lobes) with GLPG1205\n                      <jats:italic>versus<\/jats:italic>\n                      placebo, respectively. Treatment with GLPG1205\n                      <jats:italic>versus<\/jats:italic>\n                      placebo resulted in higher proportions of serious and severe treatment-emergent adverse events and treatment-emergent discontinuations, most apparent with nintedanib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Treatment with GLPG1205 did not result in a significant difference in FVC decline\n                      <jats:italic>versus<\/jats:italic>\n                      placebo. GLPG1205 demonstrated a poorer safety and tolerability profile than placebo.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01794-2022","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T12:00:31Z","timestamp":1667476831000},"page":"2201794","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial"],"prefix":"10.1183","volume":"61","author":[{"given":"Irina R.","family":"Strambu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A.","family":"Seemayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth M-C.A.","family":"Fagard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom A.K.","family":"Van der Aa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela A.","family":"de Haas-Amatsaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Modgill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Santermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric N.","family":"Sondag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Helmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2804-9511","authenticated-orcid":false,"given":"Ulrich","family":"Costabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"2024102103083741000_61.3.2201794.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2024102103083741000_61.3.2201794.2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s12325-018-0693-1","article-title":"Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK","volume":"35","author":"Strongman","year":"2018","journal-title":"Adv Ther"},{"key":"2024102103083741000_61.3.2201794.3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","article-title":"Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65\u2005years and older: incidence, prevalence, and survival, 2001\u201311","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024102103083741000_61.3.2201794.4","unstructured":"European Medicines Agency . Summary of product characteristics \u2013 Esbriet. 2011. www.ema.europa.eu\/en\/documents\/product-information\/esbriet-epar-product-information_en.pdf Date last accessed: 7 February 2022."},{"key":"2024102103083741000_61.3.2201794.5","unstructured":"European Medicines Agency . Summary of product characteristics \u2013 Ofev. 2015. www.ema.europa.eu\/en\/documents\/product-information\/ofev-epar-product-information_en.pdf Date Last accessed: 7 February 2022."},{"key":"2024102103083741000_61.3.2201794.6","unstructured":"US Food and Drug Administration . Summary of prescribing information \u2013 Esbriet. 2014. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022535s000lbl.pdf Date Last accessed: 7 February 2022."},{"key":"2024102103083741000_61.3.2201794.7","unstructured":"US Food and Drug Administration . Summary of prescribing information \u2013 Ofev. 2014. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205832s000lbl.pdf Date Last accessed: 7 February 2022."},{"key":"2024102103083741000_61.3.2201794.8","unstructured":"Ministry of Health, Labour and Welfare . Report on the Deliberation Results: Ministry of Health, Labour and Welfare; 16 September 2008. 2008. www.pmda.go.jp\/files\/000153687.pdf Date last accessed: 7 February 2022."},{"key":"2024102103083741000_61.3.2201794.9","unstructured":"Ministry of Health, Labour and Welfare . Report on the Deliberation Results: Ministry of Health, Labour and Welfare; 3 June 2015. 2015. www.pmda.go.jp\/files\/000214531.pdf Date last accessed: 7 February 2022."},{"key":"2024102103083741000_61.3.2201794.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2024102103083741000_61.3.2201794.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024102103083741000_61.3.2201794.12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2213-2600(14)70232-2","article-title":"Combination therapy: the future of management for idiopathic pulmonary fibrosis?","volume":"2","author":"Wuyts","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024102103083741000_61.3.2201794.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2018.01.009"},{"key":"2024102103083741000_61.3.2201794.14","doi-asserted-by":"crossref","first-page":"13526","DOI":"10.1021\/acs.jmedchem.0c00272","article-title":"Discovery of 9-cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a unique GPR84 negative allosteric modulator undergoing evaluation in a phase II clinical trial","volume":"63","author":"Labeguere","year":"2020","journal-title":"J Med Chem"},{"key":"2024102103083741000_61.3.2201794.15","first-page":"A1046","article-title":"Characterization of GLPG1205 in mouse fibrosis models: a potent and selective antagonist of GPR84 for treatment of idiopathic pulmonary fibrosis","volume":"199","author":"Saniere","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103083741000_61.3.2201794.16","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju027.730"},{"key":"2024102103083741000_61.3.2201794.17","doi-asserted-by":"publisher","DOI":"10.1186\/S12931-018-0918-5"},{"key":"2024102103083741000_61.3.2201794.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201706-1301OC"},{"key":"2024102103083741000_61.3.2201794.19","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1007\/s00330-021-08482-9","article-title":"Automatic quantitative computed tomography measurement of longitudinal lung volume loss in interstitial lung diseases","volume":"32","author":"Si-Mohamed","year":"2022","journal-title":"Eur Radiol"},{"key":"2024102103083741000_61.3.2201794.20","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N Engl J Med"},{"key":"2024102103083741000_61.3.2201794.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.6129"},{"key":"2024102103083741000_61.3.2201794.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00663-2018"},{"key":"2024102103083741000_61.3.2201794.23","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"key":"2024102103083741000_61.3.2201794.24","unstructured":"Galapagos NV\/Gilead Sciences . Galapagos and Gilead discontinue ISABELA phase 3 trials in IPF. 2021. www.glpg.com\/press-release\/2118\/galapagos-and-gilead-discontinue-isabela-phase-3-trials-in-ipf Date last accessed: 22 October 2022."}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01794-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:23:17Z","timestamp":1740363797000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01794-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,2]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1183\/13993003.01794-2022"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01794-2022","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}